Income Statement (TTM)
RenovoRx, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|
| Revenue | 0 | 0 | 1 |
| Change (%) | 458.14 | 175.83 | |
| % of Revenue | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 0 | |
| Change (%) | 161.70 | ||
| % of Revenue | 39.17 | 37.16 | |
| Gross Operating Profit | 0 | 0 | 0 |
| Change (%) | 239.53 | 184.93 | |
| % of Revenue | 100.00 | 60.83 | 62.84 |
| SG&A | 5 | 5 | 5 |
| Change (%) | 7.06 | 0.56 | |
| % of Revenue | 11,600.00 | 2,225.00 | 811.18 |
| R&D | 6 | 6 | 6 |
| Change (%) | 6.39 | -1.81 | |
| % of Revenue | 14,011.63 | 2,670.83 | 950.76 |
| OpEx | 11 | 12 | 12 |
| Change (%) | 7.55 | 0.56 | |
| % of Revenue | 25,611.63 | 4,935.00 | 1,799.09 |
| Operating Income | -11 | -12 | -11 |
| Change (%) | 5.78 | -3.07 | |
| % of Revenue | -25,511.63 | -4,835.00 | -1,699.09 |
| Interest Expense | |||
| Change (%) | |||
| % of Revenue | |||
| Net Income | -9 | -10 | -11 |
| Change (%) | 15.25 | 4.98 | |
| % of Revenue | -20,497.67 | -4,232.50 | -1,610.88 |
Source: Capital IQ
